#United States #Mesa #Francis Medical #Vanquish System #Prostate Ablation

Francis Medical Launches Vanquish® Procedures in Arizona for Prostate Treatment

Francis Medical, Inc., a private medical device firm, has announced a significant advancement in prostate cancer treatment with the completion of the first commercial procedures using the Vanquish® Water Vapor Ablation System in Arizona. This operation represents a notable milestone, marking the shift from clinical trial applications to everyday medical practice.

Performed by Dr. Rahul Mehan at the East Valley Urology Center in Mesa, Arizona, the procedures target localized prostate cancer, showcasing the effectiveness of the Vanquish® system, which employed high-energy sterile water vapor to ablate prostate tissue. The FDA granted the system a 510(k) clearance in November 2025, following encouraging results from the ongoing VAPOR 2 pivotal study.

Dr. Mehan expressed his enthusiasm: "Introducing Vanquish into our practice reflects our commitment to procedural innovation and enhancing patient experience. We ensure emerging technologies fit our clinical standards and priorities."

In the VAPOR 2 study, an impressive 91% of patients demonstrated the elimination of targeted, MRI-visible intermediate-risk prostate cancer after just one Vanquish procedure. The treatment recorded high patient tolerance, reporting no serious adverse events and low cases of urinary incontinence and erectile dysfunction. Patient feedback indicated minimal pain post-procedure, supporting the efficacy of this minimally invasive technique.

Mike Kujak, President and CEO of Francis Medical, emphasized the importance of these first commercial procedures, noting, "This reflects the dedication and careful planning behind our U.S. launch strategy. We are hopeful that this technology will meet the clinical expectations and become a viable alternative for men with prostate health concerns."

One year after the procedures, the VAPOR 2 study indicated that 93% of participants were satisfied with the treatment. Moreover, 94% believed that opting for this treatment was a wise choice. Continuous follow-up will further evaluate long-term outcomes, which are essential for a pre-market approval submission to expand indications for managing localized prostate cancer.

The Vanquish® system stands out in its capability to effectively target lesions throughout the prostate, addressing a significant limitation present in traditional treatment options. The company aims to revolutionize prostate cancer treatment, aligning clinical evidence with patient-centered approaches.

Founded to create innovative urological cancer therapies, Francis Medical is committed to transitioning the standard of care for prostate cancer. It aims to minimize the harsh side effects associated with existing treatments, which Francis Hoey, the company founder's father, faced during his fight against the disease.

With a focus on compassionate care and efficiency, Francis Medical strives to make treatments safer and less invasive, ultimately transforming the patient experience in prostate cancer care. For more information about their initiatives and products, visit Francis Medical.

For inquiries, contact:
Michael Kujak, CEO,
Brian Johnston, Gilmartin Group,
Shelli Lissick, Bellmont Partners.